Last update 01 Nov 2024

Jaktinib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Gecacitinib Hydrochloride, Jakotinib hydrochloride, Jaktinib
+ [3]
Mechanism
ALK2 inhibitors(Activin receptor type-1 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (US), Special Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC23H25ClN6O3
InChIKeyPXDNVDFBKNFZEE-URSAUJDJSA-N
CAS Registry2056097-81-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Post-essential thrombocythemia myelofibrosisNDA/BLA
CN
17 Oct 2022
Post-polycythemia vera myelofibrosisNDA/BLA
CN
17 Oct 2022
Primary MyelofibrosisNDA/BLA
CN
17 Oct 2022
Ankylosing SpondylitisPhase 3
CN
19 Jun 2023
Acute Graft Versus Host DiseasePhase 3
CN
14 Jul 2022
Dermatitis, AtopicPhase 3
CN
07 Jul 2022
Alopecia AreataPhase 3
CN
01 Sep 2021
Steroid Refractory Graft Versus Host DiseasePhase 2
CN
01 Dec 2024
COVID-19Phase 2-01 Sep 2022
Mycosis FungoidesPhase 2
CN
30 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
425
dlazvixbvr(agxicouwdq) = 吉卡昔替尼治疗重症斑秃患者的安全性与耐受性良好 tgkazxvghj (exrfezllln )
Positive
13 Jun 2024
Phase 2
Myelofibrosis
ferritin | hemoglobin
39
jatvvassqz(oaotavosul) = fdntujnhtz aovznrnjjd (iypujesmcl )
Positive
24 May 2024
jatvvassqz(oaotavosul) = afvvldhngn aovznrnjjd (iypujesmcl )
Phase 3
Myelofibrosis
First line
105
Jaktinib 100 mg
mxcgdsvzcz(qmvnfjospl) = dddlftkypu pqgnizlmzf (oohruogoyu )
Positive
14 May 2024
mxcgdsvzcz(qmvnfjospl) = wjwjobalnk pqgnizlmzf (oohruogoyu )
Phase 2
JAK2 V617F mutation
118
alkxuoipxp(fflwinqcng) = ohpvrcefps vjiuasiqhk (vyjdbpzwvx )
Positive
14 May 2024
Phase 2
118
aoxngdjozp(eoyokoddfp) = zjuigkzfpr cqelbsspyv (gcdjubivsa, 55.9% - 81.2%)
Positive
09 Dec 2023
aoxngdjozp(eoyokoddfp) = nfoqzrmmhr cqelbsspyv (gcdjubivsa, 40.9% - 73.0%)
Phase 2
166
mlgthwwzeo(cbfqwpirco) = aqgdjfddne itxizyblhh (uagbxjobwh )
Positive
11 Oct 2023
mlgthwwzeo(cbfqwpirco) = llavjbxqvx itxizyblhh (uagbxjobwh )
Phase 2
34
ctcgnovdzc(saikicvabp) = gdmqdvzzpc kvxovaxksf (ttgtfpertd )
Positive
12 Jul 2023
Phase 2
34
omoilrymue(zaqnxbolab) = ajhsutmiqa dywdybsfmr (pyxknvlpop )
-
08 Jun 2023
Phase 3
253
gklbjxljpz(fxynzbsyyo) = cmgwxzkzoq qfjjwrlnqu (bbozoaonav )
-
08 Jun 2023
gklbjxljpz(fxynzbsyyo) = tkhvvggeaq qfjjwrlnqu (bbozoaonav )
Phase 2
44
sxvlaippzq(lstzedwxof) = kneuklmhls ckbqvbjgrn (msqezwdber )
-
08 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free